Vivo Bio Tech Limited (511509) Fair Value & Analysis
Healthcare · IN · Market cap ₹639M (≈ $6.7M)
Strengths
Risks
Fair value as of: Aug 29, 2026
From 6 valuation models · updated today
Fair value updated Aug 29, 2026, revised from ₹91.59 to ₹33.70 (−63.2%) since Aug 13, 2026.
Below-average quality, trading 46% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (20/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (₹20.57). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (₹20.57 to ₹46.83) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 29, 2026.
How to read this chart
60‑month range ₹18.23 – ₹110.10 · fair‑value band ₹20.57 – ₹46.83 · the ₹18.23 price screens below the ₹33.70 fair value. Dashed = 300-day average. As of Aug 29, 2026.
Analysis
Vivo Bio Tech Limited (511509) currently trades at ₹18.23, while our model-based Fair Value estimate is ₹33.70, implying the stock looks roughly 84.9% undervalued today. The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Vivo Bio Tech Limited generated revenue of ₹512M at a net margin of 8.2%. Revenue declined 31.4% year over year. Net debt stands at ₹659M. The stock trades on a trailing P/E of 12.2 (as of Jul 4, 2026). Fundamentals as of Aug 29, 2026
Our scenario range runs from ₹20.57 (bear case) to ₹46.83 (bull case); at ₹18.23, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -59% fair-value upside, at 85%, 511509 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Multiples (₹40.39) versus Earnings-Based (₹12.62). Highest evidence: ROIC Compounder (72).
Notify me when 511509 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 23 · Market factors (momentum, volatility) 21
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vitro, in vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxico kinetic studies, genotoxicity screening, analytical services, etc.
Full company description
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vitro, in vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxico kinetic studies, genotoxicity screening, analytical services, etc. It also supplies SPF lab animals. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Vivo Bio Tech Limited reported revenue of ₹533M in FY2026 versus ₹514M in FY2022, a compound +0.9%/yr. Reported net income was −₹17.1M in FY2026.
Watch 511509: get an alert when its fair value changes →
Peer Group
Biotechnology · 639 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | -49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | -26% |
| argenx SE ARGX | €877.60 | €292.84 | -67% |
| Samsung Biologics Co 207940 | 1,594,000 KRW | 1,055,793 KRW | -34% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | -77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | -60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | -61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | -69% |
| BioNTech SE BNTX | $111.40 | $45.66 | -59% |
| Incyte Corporation INCY | $128.12 | $115.79 | -10% |
Compare Vivo Bio Tech Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vivo Bio Tech Limited (511509) overvalued or undervalued?
What is the fair value of 511509?
What is the quality score of 511509?
What is the revenue of Vivo Bio Tech Limited (511509)?
What is the net profit margin of 511509?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Vivo Bio Tech Limited in the live analysis
One click puts Vivo Bio Tech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.